IBS (irritable bowel syndrome) and IBD (inflammatory bowel disease) share initials, share some symptoms, and are frequently confused — by patients, by primary care physicians, and occasionally in initial diagnoses. This confusion is not harmless: IBD (Crohn's disease and ulcerative colitis) causes progressive intestinal damage and requires medical intervention to prevent serious complications. IBS is a functional disorder with no structural damage and a very different treatment approach. Misidentifying IBD as IBS leads to delayed treatment and disease progression.
These symptoms suggest IBD or another serious condition and should NOT be attributed to IBS without proper evaluation:
Fecal calprotectin: The most useful non-invasive test for distinguishing IBS from IBD. Calprotectin is a protein released by white blood cells in inflamed intestinal tissue — levels are elevated in IBD and normal in IBS. A calprotectin level under 50 µg/g in a symptomatic patient makes IBD very unlikely; levels above 250 µg/g warrant colonoscopy. This test can prevent unnecessary colonoscopies in IBS patients while reliably flagging those who need one.
CRP (C-reactive protein) and ESR: General inflammatory markers that are typically elevated in active IBD and normal in IBS. Less specific than calprotectin but cheap and universally available.
Colonoscopy with biopsy: The definitive test for IBD. In ulcerative colitis: continuous inflammation from the rectum extending proximally, with characteristic pseudopolyps and granularity. In Crohn's: skip lesions (patches of inflammation with normal mucosa between), transmural inflammation, possible fistulas, any part of the GI tract from mouth to anus.
| Aspect | IBS Treatment | IBD Treatment |
|---|---|---|
| First-line | Low-FODMAP diet, fiber optimization, stress management | Aminosalicylates (mesalamine) for mild UC; corticosteroids for flares |
| Moderate disease | Antispasmodics, loperamide, gut-brain directed therapies (CBT, hypnotherapy) | Immunomodulators (azathioprine, 6-MP); biologic therapy (infliximab, adalimumab) |
| Gut microbiome | Probiotics (L. plantarum, Bifidobacterium) modestly effective; key target | FMT shows promise in UC remission induction; under active investigation |
| Surgery | Not indicated (surgery doesn't cure IBS) | Required in ~25% of Crohn's patients; ~30% UC patients eventually need colectomy |
| Monitoring | Symptom tracking; no imaging/scope surveillance | Regular colonoscopy for dysplasia surveillance; blood work every 3–6 months |